U.S. markets open in 9 hours 1 minute
  • S&P Futures

    3,275.75
    -26.50 (-0.80%)
     
  • Dow Futures

    26,375.00
    -182.00 (-0.69%)
     
  • Nasdaq Futures

    11,211.25
    -131.50 (-1.16%)
     
  • Russell 2000 Futures

    1,549.80
    -8.60 (-0.55%)
     
  • Crude Oil

    36.38
    +0.21 (+0.58%)
     
  • Gold

    1,875.80
    +7.80 (+0.42%)
     
  • Silver

    23.58
    +0.22 (+0.96%)
     
  • EUR/USD

    1.1692
    +0.0014 (+0.12%)
     
  • 10-Yr Bond

    0.8350
    -0.7810 (-100.00%)
     
  • Vix

    37.59
    -40.28 (-100.00%)
     
  • GBP/USD

    1.2928
    +0.0005 (+0.04%)
     
  • USD/JPY

    104.3970
    -0.2130 (-0.20%)
     
  • BTC-USD

    13,411.41
    -75.82 (-0.56%)
     
  • CMC Crypto 200

    263.21
    +20.53 (+8.46%)
     
  • FTSE 100

    5,581.75
    -1.05 (-0.02%)
     
  • Nikkei 225

    23,192.20
    -139.74 (-0.60%)
     

New Alzheimer's drug touted

A new research note makes a bullish case for Biogen Idec's BIIB037 experimental drug for Alzheimer's disease. RBC Capital Markets predicted it will make a big splash at an Alzheimer's and Parkinson's diseases conference in France next week. The biotech will likely show "best in class" data for the drug when it makes its presentation on March 20, the report said, adding that BIIB037 could be "one of the biggest potential drugs in all of the biopharma industry" if it ends up making it to market. Biogen shares fell 1.5% to 408.11 .